NCT05480592View on ClinicalTrials.gov

A Study of HS-10380 in Chinese Participants

PHASE1UnknownINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

July 30, 2023

Conditions
Schizophrenia
Interventions
DRUG

HS-10380

Administered orally as a tablet

DRUG

Placebo

Administered orally as a tablet

Trial Locations (1)

200030

RECRUITING

Shanghai Mental Health Center, Shanghai

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

NCT05480592 - A Study of HS-10380 in Chinese Participants | Biotech Hunter | Biotech Hunter